Jonathan Violin is CEO at Viridian Therapeutics, Inc.\DE (VRDN). They have made 6 open-market trades across 1 company since 2022, most recently 2026-01-23.
CIK 0001730615
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VRDN | SELL | 2023-02-02 | 2023-02-07 | $36.80 | $3.7M | -3.7% | -14.3% | -25.5% |
| VRDN | SELL | 2022-06-01 | 2022-06-02 | $12.20 | $366K | -14.1% | -9.8% | +78.4% |
| VRDN | SELL | 2022-05-02 | 2022-05-04 | $13.04 | $391K | +12.2% | +0.7% | +19.0% |
| VRDN | SELL | 2022-04-01 | 2022-04-05 | $18.92 | $1.1M | -8.7% | -42.1% | -39.5% |
| VRDN | SELL | 2022-03-01 | 2022-03-03 | $17.65 | $1.1M | +16.2% | +10.4% | -29.2% |
| VRDN | SELL | 2022-02-01 | 2022-02-03 | $19.09 | $1.1M | +2.4% | -15.6% | -39.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.